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Abstract
The regenerative potential declines upon aging. This might be due to cell-intrinsic changes in stem and progenitor cells or
to influences by the microenvironment. Mesenchymal stem cells (MSC) raise high hopes in regenerative medicine. They are
usually culture expanded in media with fetal calf serum (FCS) or other serum supplements such as human platelet lysate
(HPL). In this study, we have analyzed the impact of HPL-donor age on culture expansion. 31 single donor derived HPLs (25
to 57 years old) were simultaneously compared for culture of MSC. Proliferation of MSC did not reveal a clear association
with platelet counts of HPL donors or growth factors concentrations (PDGF-AB, TGF-b1, bFGF, or IGF-1), but it was
significantly higher with HPLs from younger donors (,35 years) as compared to older donors (.45 years). Furthermore,
HPLs from older donors increased activity of senescence-associated beta-galactosidase (SA-bgal). HPL-donor age did not
affect the fibroblastoid colony-forming unit (CFU-f) frequency, immunophenotype or induction of adipogenic
differentiation, whereas osteogenic differentiation was significantly lower with HPLs from older donors. Concentrations
of various growth factors (PDGF-AB, TGF-b1, bFGF, IGF-1) or hormones (estradiol, parathormone, leptin, 1,25 vitamin D3)
were not associated with HPL-donor age or MSC growth. Taken together, our data support the notion that aging is
associated with systemic feedback mechanisms acting on stem and progenitor cells, and this is also relevant for serum
supplements in cell culture: HPLs derived from younger donors facilitate enhanced expansion and more pronounced
osteogenic differentiation.
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Introduction
Regeneration of human tissues is accomplished by adult stem
and progenitor cells. The regenerative potential decays upon aging
and therefore, aging can be interpreted as loss of function in
somatic stem cells [1]. Mesenchymal stem cells (MSC) resemble
precursor cells for various mesodermal lineages such as adipocytes,
chondrocytes and osteocytes [2,3]. They can be isolated from
many tissues and culture expanded over several passages.
However, MSC preparations are heterogeneous and only a subset
possesses multilineage-differentiation potential - therefore it may
be more appropriate to alternatively use the term ‘‘mesenchymal
stromal cells’’ [4–6].
The ease of culture expansion of MSC has raised high hopes for
a broad range of applications in regenerative medicine [7]. On the
other hand, culture conditions have major impact on the
composition of cell preparations and their functional potency
[8]. The potency is not necessarily reflected by proliferation or in
vitro differentiation potential – it is rather important how these cell
preparations perform under in vivo conditions of a specific clinical
setting. Fully defined synthetic culture media would be preferable
for standardization of therapeutic products. However, despite
intensive research serum additives usually need to be added. To
date, fetal calf serum (FCS; alternatively termed ‘‘fetal bovine
serum’’ [FBS]) is the most commonly used serum supplement. In
the light of clinical application there is emerging interest to avoid
the use of FCS due to the risk of xenogenic immune reactions,
infections with bovine viruses or prions and a high batch-to-batch
variation [9,10]. In contrast, various types of human supplements
have been shown to serve as substitute for animal serum in clinical-
scale expansion of MSC such as 1) human serum [11], 2) human
thrombin-activated platelet releasate in plasma [12], 3) platelet
rich plasma (PRP) [13] or 4) human platelet lysate (HPL). The
later can be generated from platelet units which derived from
apheresis. HPL has proven as very efficient substitute for FCS and
many laboratories have changed their culture conditions accord-
ingly [12,14–16].
Human platelet lysate is generated by a simple freeze-thaw
procedure of platelet units – thus, it is rich in growth factors
released from the platelet fraction. These growth factors include
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beta 1 (TGF-b1), insulin like growth factor (IGF-1) and basic
fibroblast growth factor (bFGF) [17–19]. This might explain the
consistently higher proliferation and culture expansion rate of
MSC in HPL media in comparison to FCS [12,13,16,20,21]. To
minimize batch-to-batch variation, individual HPLs are usually
pooled but this entails higher risks of immunological consequences
or viral infections as each unit is a potential source of pathogens
[22]. Recently, we have demonstrated that there is some variation
in 10 HPLs derived from single donor apheresis samples [21].
HPLs from platelet units with higher platelet counts or with higher
PDGF concentrations seemed to enhance culture expansion of
MSC. Reanalysis of the data indicated that there might also be an
age-associated effect on proliferation. However, due to the low
number of samples, no statistical analysis was feasible.
Indeed, age-associated effects of serum supplements were
already proposed in 1921 when cell culture methods were still in
its infancy [23,24] and more recently this was supported in breast
cancer cell lines [25] and in rat MSC [26]. On the other hand,
enhanced cell growth with human serum from younger donors
was not observed in several other studies [27–29]. Therefore, the
question remains if donor age of HPL affects MSC expansion or
in vitro differentiation.
In the present study we sought to further address variation
between individual HPLs and to identify relevant parameters for
culture expansion of MSC from either bone marrow or adipose
tissue. We have directly compared 31 individual HPLs with regard
to proliferation, fibroblastoid colony-forming unit (CFU-f) fre-
quency, expression of SA-bgal, immunophenotype as well as
adipogenic and osteogenic differentiation. Subsequently, the
variation in MSC growth was correlated with concentrations of
various growth factors and hormones - however, the most
significant association was observed with HPL-donor age.
Materials and Methods
Ethics Statement
This study was approved by the Ethic Committee of the
University of Aachen and all samples were isolated after written
consent. MSC derived from bone marrow of the caput femoris taken
during hip replacement surgery (permit number EK128/09).
MSC from adipose tissue were isolated from lipoaspirates of
healthy young patients undergoing cosmetic surgery (permit
number EK163/07).
Generation of Human Platelet Lysate
Human platelet lysates (HPLs) were generated from platelet units
that were harvested from individual healthy donors by apheresis
usingtheTrimaAccelCollectionSystem(CaridianBCT,Garching,
Germany). The donors are examined closely - they have to be in
healthy condition and between 18 and 65 years old (therefore the
available age-range for HPL is limited). Thrombocyte concentrates
haveaplateletcontentof2.0to4.2610
11plateletsin200 mLplasma
supplemented with Acid-Citrate-Dextrose (ACD) (1:11 v/v). After
theirexpirydate(fivedaysafterharvesting)plateletunitswerefrozen
twice at 280uC and re-thawed at 37uC. To remove membrane
fragments, lysates were centrifuged at 26006g for 30 min and the
supernatant was filtered through 0.2 mm GD/X PVDF filters
(Whatman,Dassel,Germany).HPLswerestoredat280uCuntiluse
and2 U/mLheparinwasaddedtoavoidgelatinization.Inthisstudy
we have used 31 HPLs of 25 to 57 year old donors. Distribution
among bloodtypeswas A:17,B:3,AB: 2,and 0:9samples.In order
to exclude any possible effect of gender only male samples were
considered.
Quantification of Growth Factors and Hormones in HPL
The amount of PDGF-AB in the HPL was assayed with the
Quantikine Human PDGF-AB enzyme-linked immunoabsorbent
assay (ELISA; R&D Systems, Abingdon, UK). bFGF was analyzed
with the Quantikine Human bFGF ELISA kit (R&D Systems).
TGF-b1 was assayed with the RayBio Human TGF-b1 ELISA kit
(Raybiotech, Norcross, GA, USA) after activation of latent TGF-
b1 to the immunoreactive form according to manufacturer’s
instructions. Human leptin was assessed with the Human Leptin
ELISA (Biovendor, Brno, Czech Republic). ELISAs were quan-
tified by measuring the absorbance with a plate reader (Tecan
Infinite M200; Tecan Deutschland GmbH, Crailsheim, Germany)
at 450 nm with a reference wavelength of 540 nm. 1,25 vitamin
D3 was analyzed with the IDS 1,25 Dihydroxy Vitamin D enzyme
immunoassay (EIA, IDA Ltd, Boldon, UK). IGF-1 and growth
hormone were assayed with solid-phase, enzyme-labeled chemi-
luminescent assays (Immulite 2000 system, Siemens Healthcare
Diagnostic Products Ltd, Llanberis, UK). These assays were
quantified by measuring the absorbance with the Wallac Victor
2
plate reader (PerkinElmer, Waltham, MA, USA). Estradiol and
parathormone were analyzed with electrochemiluminescence
immuno assays (ECLIA) with a cobas e 411 system (Roche
Diagnostics GmbH, Mannheim, Germany).
Cell Culture Conditions
Bone marrow (BM)-derived MSC were isolated from the caput
femoris from patients undergoing hip replacement surgery as
described before [21,30] (n=11; Table 1). It needs to be taken into
account that these are predominantly elderly patients who are
more susceptible to osteoporosis and therefore the cellular
composition of these may differ from bone marrow aspirates of
healthy younger donors [31,32]. Briefly, bone fragments were
flushed with PBS and mononuclear cells (MNC) were subsequently
isolated by density gradient on Biocoll (Biochrom AG, Berlin,
Germany).
Adipose tissue (AT)-derived MSC were isolated from lipoaspi-
rates that were washed in 9 g/L NaCl, centrifuged at 3006g for
Table 1. MSC donor age and gender.
MSC donor age gender
Bone marrow derived MSC:
BM-MSC 1 70 female
BM-MSC 2 73 female
BM-MSC 3 55 female
BM-MSC 4 65 male
BM-MSC 5 65 female
BM-MSC 6 76 male
BM-MSC 7 63 female
BM-MSC 8 68 male
BM-MSC 9 69 female
BM-MSC 10 48 female
BM-MSC 11 77 female
Adipose tissue derived MSC:
AT-MSC 1 19 male
AT-MSC 2 35 male
AT-MSC 3 53 male
doi:10.1371/journal.pone.0037839.t001
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2 g/L collagenase type I (Biochrom; specific activity 125–250
Mandl Units/mL of powder substance) for 45 min at 37uCo na
horizontal rotary shaker [20]. The digested tissue was passed
through a 100 mm cell strainer (BD Biosciences, Franklin Lake,
NJ, USA) and re-suspended in corresponding culture media. In
this study we used AT-MSC from three different donors (Table 1).
Cell culture was performed in polystyrene cell culture dishes
(Greiner, Kremsmu ¨nster, Austria). Culture medium consisted of
Dulbeccos Modified Eagles Medium-Low Glucose (DMEM-LG;
PAA, Pasching, Austria) with 2 mM L-glutamine (Sigma-Aldrich,
St. Louis, MO, USA) and 100 U/mL penicilline/streptomycine
(pen/strep; Lonza, Basel, Switzerland). Culture medium was
supplemented with 10% FCS (HyClone, Bonn, Germany) or 10%
HPL of individual donors as indicated in the text. The first
medium exchange was performed after 48 hours to remove
erythrocytes and other non-adherent cells. Thereafter, medium
was changed twice per week.
Some experiments were performed with MSC which were
freshly isolated from bone marrow using different HPLs (CFU-f
analysis and immunophenotype). For other experiments the
MSC were expanded with the same HPL supplement for several
passages to provide a comparable starting population for
subsequent comparison of different HPLs (proliferation assays,
long-term expansion curves and SA-bgal activity). When
reaching 80% confluence, cells were trypsinized, counted in a
Neubauer counting chamber (Brand, Wertheim, Germany) and
replated at 1,000 cells/cm
2. Cell Population doublings per
passage (PDP) and cumulative population doublings (CPD) were
calculated from the time when culture media with the different
HPL supplements were tested in parallel (passage 2 for long-term
growth curves) and calculated as described in our previous work
[20,33].
Proliferation Assay
Cell proliferation was assessed via the Thiazolyl Blue Tetrazo-
lium Bromide (MTT) assay [34]. Cells of passage 4 to passage 7
were seeded on a 96-well plate (100 cells per well) with different
serum supplements as described above. After 7 days, cells were
washed and incubated with 1 mM 3-(4,5-Dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma-Aldrich) in
PBS for 3.5 hours. The excess solution was discarded and crystals
were resolved in 4 mM HCl in isopropanol (both from Roth,
Karlsruhe, Germany). Optical density was measured at a
wavelength of 590 nm with a reference wavelength of 620 nm
using the Tecan Infinite M200 plate reader.
Analysis of Senescence-associated b-galactosidase
Activity
Senescence-associated b-galactosidase (SA-bgal) activity was
assessed by a fluorescence-based assay using flow cytometry [35].
MSC of either passage 3, 5, or 6 (1,000 cells per cm
2) were
cultured in parallel with different HPLs. After 5 to 6 days sub-
confluent cells were incubated with 100 nM Bafilomycin A1
(Sigma-Aldrich) for 1 hour to alkalize the lysosomes. Cells were
then incubated for 2 hours with 33 mL of 2 mM 5-dodecanoyla-
minofluorescein-di-b-D-galactopyranoside (C12FDG, Invitrogen,
Carlsbad, CA, USA), washed thoroughly and analyzed with a
FACSCanto II (BD Biosciences). Data were analyzed with
WinMDI (Windows Multiple Document Interface for Flow
Cytometry) software (TreeStar, Ashland, OR, USA).
Analysis of Colony Formation
Freshly isolated MNC were counted in a Neubauer counting
chamber and seeded in different dilutions on 24-well plates
(250,000; 100,000; 50,000; 20,000; 6,000; 2,000 and 1,000 cells
per well). After 8 days, the plastic adherent colonies were stained
with crystal violet (Fluka Analytical, Buchs, Switzerland). We have
chosen those dilutions for further analysis which facilitated clear
separation of fibroblastic colony-forming units (CFU-f). Colonies
consisting of more than 20 cells were taken into account.
Subsequently, colony size was reanalyzed in cryopreserved 24-
well plates by counting of cells per colony.
Immunophenotypic Analysis
Immunophenotypic analysis was performed during the primary
passage upon culture-isolation of MSC in different HPLs. Primary
culture was performed for three weeks to generate enough cells
and non-adherent hematopoietic cells were washed away by rigid
medium exchanges. Expression of surface markers was analyzed
with a FACSCanto II (BD Biosciences) using the following
monoclonal antibodies: mouse anti-human CD14-APC (clone
M5E2), CD29-PE (clone MAR4), CD31-PE (clone WM59),
CD34-APC (clone 8G12), CD45-APC (clone HI30), CD73-PE
(clone AD2), CD90-APC (clone 5E10), CD140a-PE (clone aR1)
(all from BD Biosciences), CD105-FITC (clone MAR-226;
ImmunoTools, Friesoythe, Germany), CD271-APC (clone
ME20.4-1.H4; Miltenyi Biotech, Bergisch Gladbach, Germany).
Data were analyzed with WinMDI software.
In vitro Differentiation
Osteogenic and adipogenic differentiation of BM-MSC was
performed as described before [2,30]. In brief, culture media was
changed to adipogenic or osteogenic differentiation media
supplemented with either 10% FCS or 10% of the corresponding
HPL to assess the impact of individual HPLs on differentiation.
Adipogenic differentiation media consisted of DMEM-High
Glucose with 2 mM L-glutamine, 1 mM dexamethasone, 0.5 mM
1-methyl-3-isobutylxanthin (IBMX), 10 mg/mL insulin (all from
Sigma-Aldrich) and 100 U/mL pen/strep (Lonza). Medium was
changed twice per week. After three weeks, fat droplet formation
uponadipogenicdifferentiationwasstainedwithOilRedO(Sigma-
Aldrich),extractedwith99%isopropanol(Roth)andquantifiedwith
the Tecan Infinite M200 plate reader at a wavelength of 550 nm
with a reference wavelength of 650 nm. Alternatively, wells were
stained with the green fluorescent dye BODIPY (4,4-difluoro-
1,2,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene) and coun-
terstained with DAPI (49,6-Diamidin-2-phenylindol; both Molecu-
lar Probes, Eugene, Oregon, USA) as described previously [36].
Microscopic images were taken with a Leica DM IL HC
fluorescence microscope (Leica, Wetzlar, Germany).
Osteogenic differentiation media consisted of DMEM-LG
(PAA) with 2 mM L-glutamine, 100 nM dexamethasone,
200 mM L-ascorbic acid-2-PO4,1 0m Mb-glycerophosphate (all
Sigma-Aldrich) and 100 U/mL pen/strep (Lonza). Medium was
changed twice per week. After two weeks, osteogenic differenti-
ation was analyzed upon staining with Alizarin S Red with the
Tecan Infinite M200 plate reader at a wavelength of 550 nm with
a reference wavelength of 650 nm. Additionally, images were
taken with a Leica DM IL HC microscope.
Statistics
Results are expressed as mean 6 standard deviation or as a box-
and-whisker plot where the whiskers represent the minima and
maxima. Linear regression analysis was performed with Excel
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we have adopted the Student’s T-test. Probability value of P,0.05
denoted statistical significance.
Results
The Proliferation Rate of MSC Varies between Platelet
Lysates
Thirty-one single donor derived HPLs were compared for
culture expansion of MSC from bone marrow (BM) or adipose
tissue (AT). MSC at passage 4 to 7 were seeded in parallel with
culture media which were supplemented with 10% of one of these
HPLs. As a reference, we have used 10% FCS. After 7 days
proliferation was measured with the MTT assay. AT-MSC
proliferation was about 5.1-fold higher with HPL than with FCS
(P=0.01), whereas this growth stimulation was less pronounced in
BM-MSC (1.4-fold; P=0.27). The proliferation rate varied in
culture media supplemented with different HPLs, and these
differences were consistently observed with different MSC
preparations (BM-MSC, n=4; AT-MSC, n=3).
Next, we aimed to identify relevant factors for MSC growth.
The proliferative effect of HPL correlated only moderately with
platelet counts of the HPL donors (Figure S1A,B). Concentrations
of PDGF-AB, bFGF, TGF-b1 and IGF-1 were measured in the
HPLs using commercially available ELISA kits. These growth
factors revealed some variation between HPLs - however, none of
them correlated significantly with the proliferation of MSC (Figure
S1C–J). Furthermore, there was no association between blood
groups of HPL and cell growth. Therefore, these parameters do
not seem to be of major relevance for MSC growth.
Platelet Lysate of Young Donors Increases Proliferation
Subsequently, we analyzed if the variation in MSC growth
correlated with the donor age of individual HPLs. Overall, the
growth promoting effect of HPLs decreased upon aging, and this
was observed in different MSC preparations from bone marrow
(n=4) and adipose tissue (n=3; Figure 1). These differences were
significant comparing the lower and the upper quartile Q1 and Q3
(Q1: ,35 years, n=8, mean age 30; Q2:35 to 45 years, n=16,
mean age 42; and Q3: .45 years, n=7, mean age 52; BM-MSC:
P=0.008; AT-MSC: P=0.05). To exclude the effect that MSC
donor age may have on cell growth rate, each cell preparation was
simultaneously cultured with the 31 different HPL supplements. In
average, proliferation of MSC with HPLs of younger donors was
about 1.4-fold higher than with HPLs of elderly donors.
Subsequently, we have analyzed if higher proliferation with
HPL of younger donors is maintained over several passages. To
this end, MSC at passage 2 were further expanded in parallel with
either five HPLs of young donors (25–31 years) or five HPLs of
older donors (50–57 years). After five additional passages MSC
gained in average 1.3 additional cumulative population doublings
when they were cultured with HPL of younger donors as
compared to older donors (10.33 CPD versus 8.99 CPD;
P,0.01). The deviance increased from passage to passage
(Figure 1E). These results demonstrate that age-associated changes
in HPL supplements are relevant for proliferation of MSC.
Senescence-associated b-galactosidase Activity Increases
with HPL of Older Donors
HPL-donor age might also be relevant for cellular aging of MSC
in culture. Therefore, we cultured BM-MSC with HPL of young
(,35 years; n=8) or older donors (.45 years; n=7) for five to six
days and determined activity of senescence-associated beta-galac-
tosidase (SA-bgal). This lysosomal enzyme permits identification of
senescent cells in culture and can be quantified by flow cytometry
[35]. Overall, the mean signal intensity of the fluorogenic substrate
5-dodecanoylaminofluorescein di-b-D-galactopyranoside
(C12FDG) significantly increased with HPL of elderly donors
(P=0.02;Figure2).Thus,HPLdonorageisassociatedwithactivity
of this biomarker for cellular senescence.
HPL-donor Age does not Affect CFU-f
Subsequently, we analyzed whether the initial frequency of
fibroblastoid colony units (CFU-f) is affected by different HPLs.
BM-MSC were isolated and cultured in parallel in culture media
containing the 31 different HPLs. CFU-f frequency was
determined after 8 days. Overall, CFU-f frequency was about
3.3-fold higher with HPL as compared to FCS (P=0.05). There
was notoriously some variation between different bone marrow
samples (n=3) and between different HPLs. No correlation was
observed between CFU-f frequency and HPL-donor age
(Figure 3A,B). Overall, colonies were larger if cultured with
HPL of younger donors (Q1: mean colony size 186 cells) as
compared to HPL of older donors (Q3: mean colony size 139 cells)
although these results were not significant (P=0.09). Furthermore,
CFU-f frequency did not correlate to concentrations of PDGF-AB,
bFGF, TGF-b1 and IGF-1 in the HPLs (data not shown).
Immunophenotypic Analysis of MSC
MSC are commonly characterized by a panel of surface
markers [6]. To address whether HPL-donor age has impact on
the immunophenotype of MSC, cells were isolated in parallel from
fresh bone marrow with FCS, HPLs of young (,35 years; n=5) or
older donors (.45 years; n=5). Immunophenotypic analysis
revealed hardly any contamination of remaining CD45
+ blood
cells. All MSC preparations revealed the typical surface marker
profile for MSC: CD29
+, CD73
+, CD90
+, CD105
+, CD14
2,
CD31
2, CD34
2, CD45
2, CD140
+, and CD271
low (Figure 3C).
The percentage of positive cells was not affected by HPL of young
or elderly donors. Notably, expression of CD140a (PDGF-
Receptor a) was higher in MSC cultured with HPL as compared
to those cultured with FCS (P=0.03; Figure 3D).
In vitro Differentiation of MSC
Subsequently, we assessed if the in vitro differentiation potential
of BM-MSC was influenced by the different HPLs. Adipogenic
differentiation was analyzed by staining of lipid droplets with Oil
Red O and quantification on a plate reader. Alternatively, the
number of differentiated cells was determined with BODIPY
staining. There were reproducible differences in adipogenic
differentiation with different HPLs, but there was no correlation
with growth factor concentrations or HPL-donor age
(Figure 4A,B).
Osteogenic differentiation was determined by staining of
calcium phosphate precipitates with Alizarin S Red and quanti-
fication using a plate reader. Overall, osteogenic differentiation
was higher in HPLs derived from younger donors. This notion was
supported by classification of HPLs in a younger (Q1, ,35 years)
and older group (Q3, .45 years; P=0.04; Figure 5C–E). These
results are in line with a previous report indicating that osteogenic
differentiation but not adipogenic differentiation is impaired with
serum of elderly donors [28].
Growth Factors and Hormones in HPL
We reasoned that the HPL-donor age-associated differences in
growth stimulation, SA-bgal activity and osteogenic induction
might correlate with concentrations of specific growth factors or
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37839Figure 1. Proliferation is associated with HPL-donor age. Mesenchymal stem cells from bone marrow (BM-MSC; n=4) or adipose tissue (AT-
MSC; n=3; passage numbers are indicated) were cultured for seven days with media supplemented with different HPLs. Subsequently, proliferation
was assessed via MTT assay and normalized to cell growth with FCS. Proliferation was higher in media supplemented with HPLs of younger donors in
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Therefore, we have compared PDGF-AB, bFGF, TGF-b1, IGF-
1, estradiol, leptin, parathormone and 1,25 vitamin D3 in HPL of
young (,35 years) and elderly donors (.45 years). There were no
significant age-associated differences in concentrations of these
factors (Figure 5).
Discussion
Cellular communication with an aging environment affects the
regenerative potential. This has been suggested by parabiosis
pairings of mice with a shared circulatory system. Heterochronic
parabioses of young and aged mice continuously provide serum of
young animals to their aged counterpart and this rejuvenates
activation of aged satellite cells and proliferation of aged liver
progenitor cells [37]. Therefore, age-associated changes are not
only cell-intrinsically determined, but they are also governed by
systemically released factors. Our results indicate that similar
mechanisms can also be attributed in cell culture: HPLs from
younger donors stimulate proliferation of MSC and enhance their
osteogenic differentiation as compared to HPLs from older donors.
Notably, also the activity of senescence-associated b-galactosidase
increased using HPLs of older donors. This is in line with a recent
study of Zhang and co-workers who demonstrated increased
proliferation and more SA-bgal positive cells with pooled serum of
older rats (64–68 weeks old) as compared to younger rats (3–4
weeks old) [26]. Replicative senescence in vitro is certainly not
identical with the complex changes during aging of the organism,
but there is evidence that molecular changes in long-term culture
and aging are related [38,39]. Zhou and co-workers demonstrated
that at passage 2 more MSC are positive for SA-bgal in MSC
derived from older than from younger subjects [40]. Thus, the
increased SA-bgal activity with HPL of older donors indicates that
aging of MSC is enhanced by serum supplements of elderly
donors.
In this study, we have always supplemented 10% of either FCS
or HPL. We have chosen this concentration as it is often used for
standardized expansion procedures [41]. However, FCS and HPL
are much different materials and this renders a direct comparison
of the two serum supplements at a given concentration difficult.
HPL enhanced proliferation 1.4-fold in MSC derived from bone
marrow and even 5.1-fold in MSC from adipose tissue as
compared to FCS. These results correspond to our previous
observations that especially proliferation of AT-MSC is increased
with HPL [20,21] providing evidence that MSC from different
tissues are distinct in their nutritional requirements. It is even
anticipated that BM-MSC, which are either derived from caput
femoris or from bone marrow aspirates from the iliac crest, reveal
differences in cell growth and differentiation. The growth
promoting effect of HPL is probably due to growth factors or
other specific compounds which are released from the platelet
fraction. It has been controversially discussed whether PDGF-AB
is relevant for MSC proliferation [42–46]. In our previous work,
we have analyzed 10 HPLs with RayBiotech Chemokine
membranes and the evaluation revealed that PDGF-AB had the
best association with MSC proliferation. However, this is not
confirmed by our present study with more precise ELISA
measurements and a higher number of HPL samples. PDGF-AB
is the most abundant isoform and binds to the receptor-subtypes
PDGF-Raa and PDGF-Rab – it does not bind to PDGF-Rbb
which has recently been associated with proliferation and
preservation of stem cell function in MSC [45,47]. bFGF, TGF-
all biological replica derived from bone marrow (A,B) and adipose tissue (C,D). For statistical analysis HPLs were classified in three age-groups: ,35
years, 35 to 45 years, and .45 years (B,D). MSC at passage 2 were simultaneously cultured for 5 additional passages with HPL derived from 5 young
and 5 older donors (E). **P,0.01; *P,0.05.
doi:10.1371/journal.pone.0037839.g001
Figure 2. HPL-donor age is associated with activity of senescence-associated b-galactosidase. MSC were cultivated for 5–6 days in HPL
media of younger (,35 years; n=8) or older donors (.45 years, n=7). C12FDG, a fluorogenic substrate of SA-bgal was subsequently analyzed by flow
cytometry. A representative histogram of fluorescence intensity is demonstrated (grey line: autofluorescence; blue line: youngest HPL donor; red line:
oldest HPL donor). Comparison of mean fluorescence intensity between the age-groups revealed higher SA-bgal activity with HPL of older donors (B).
*P,0.05.
doi:10.1371/journal.pone.0037839.g002
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growth [17,18,48], whereas a growth-stimulatory effect was not
observed in other studies [42,49]. Our study did not reveal
significant correlation for any of these growth factors with MSC
growth indicating that their concentration is not growth-limiting.
Interestingly, the most abundant correlation for MSC prolifer-
ation was observed with HPL-donor age: cell growth was
enhanced with serum from younger donors. This was observed
with MSC derived from bone marrow of the caput femoris and
from adipose tissue. Furthermore, the same tendency was also
Figure 3. Fibroblastoid colony forming unit (CFU-f) frequency and immunophenotype. Mononuclear cells were isolated from bone
marrow and seeded in dilution series with media containing 31 different HPLs or FCS – these experiments were performed with three individual MSC
preparations. CFU-f frequency was assessed after 7 days via crystal violet staining (A). CFU-f frequency varied between different MSC preparations, but
there was no association with HPL-donor age within either of the MSC preparations (B). Subsequently, cell preparations were expanded for one
additional passage. Flowcytometry revealed the commonly described surface marker profile for MSC (C; autofluorescence= black line). HPLs derived
from younger donors (,35 years; n=5), or HPLs derived from older donors (.45 years; n=5) did not have significant impact on the
immunophenotype (D). *P,0.05; scale bar=500 mm.
doi:10.1371/journal.pone.0037839.g003
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two female samples [21]. On the other hand, age-associated effects
of serum supplements were not observed in other studies [27–29]
which might be due to the use of serum instead of HPL. These
effects might also be abrogated with other cell types such as
fibroblasts [29], or by examining female serum exclusively [28].
Furthermore, cell preparations change continuously in the course
of culture expansion, and therefore HPL-donor age may also exert
different effects on very early or very late passages [30,50].
Notably, HPL-donor age did not influence CFU-f frequency. For
this analysis we considered large and very small colonies as well –
therefore CFU-f frequency is particularly influenced by the
percentage of cells which are capable of surface adherence and
outgrowth. In contrast, proliferation is rather reflected by colony
size. As expected, colonies consisted of more cells if cultured with
HPL of younger donors although this was not significant. The age-
associated effect of individual serum supplements would be levelled
by pooling of large numbers of HPLs to generate a consistent lot
[51]. On the other hand, this might increase the risk of infection
with pathogens such as human immunodeficiency virus (HIV) or
hepatitis B and C. In contrast to thrombocyte concentrates, which
need to be used freshly, it is possible to quarantine frozen-stored
HPL [52]. HPL-donors may then be tested after an interval of
several months to reduce the risk, but even so it may be safer to use
only one or few HPLs.
Several studies have shown an inverse relationship between
MSC-donor age and the replicative life span of MSC and
fibroblasts [53–55]. This effect is usually relatively small with a
high variation between different donor samples [32,56]. In this
study, we did not use enough samples to address such inter-
individual differences. Either way, the effect of MSC-donor age
was not the focus of this study but the effect of HPL-donor age.
Therefore, all MSC preparations were always cultured in parallel
with each of the 31 HPL-supplements.
Osteoporosis and reduction of bone formation are major
problems for elderly people. It is conceivable that MSC of
Figure 4. In vitro differentiation of MSC in relation to HPL-donor age. Bone marrow derived MSC were differentiated towards adipogenic
(A,B) or osteogenic lineage (C–E) using induction media supplemented with different HPLs. After 3 weeks adipogenic differentiation was assessed by
staining of lipid droplets with Oil Red O or BODIPY (nuclei were counterstained with DAPI) in comparison to non-differentiated controls (A).
Quantitative analysis did not reveal any association between adipogenic differentiation and HPL-donor age (B; n=3). Osteogenic differentiation was
analyzed after two weeks by staining of calcium phosphate precipitates with Alizarin S (C). HPLs of younger donors stimulated osteogenic
differentiation more than HPLs of elderly donors (D; n=3). For statistical analysis HPLs were classified in three age groups: ,35 years, 35 to 45 years,
and .45 years (E). *P,0.05; scale bar=100 mm.
doi:10.1371/journal.pone.0037839.g004
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such cell-intrinsic differences our study demonstrated that the
osteogenic differentiation potential was reduced in each of the
BM-MSC preparations if cultured with HPL of elderly donors.
These results support previous observations by Abdallah and co-
workers [28]. The analogy of decreased bone formation upon
aging and reduced osteogenic induction with HPL of older donors
indicates that soluble serum factors may contribute to decreased
bone formation and osteoporosis. Further comparison of serum
derived from osteoporotic and non-osteoporotic donors is neces-
sary to demonstrate if systemically released compounds contribute
to this disease.
So far, our analysis did not unravel relevant age-associated
growth factors. Only PDGF-AB correlated moderately with
osteogenic differentiation. It is conceivable that growth factors
act synergistically and this might be addressed with mathematical
models based on larger sample numbers. Other metabolites such
as lipids and hormones may also be participating in functional
regulation. It is also possible that HPL comprises microvesicles or
exosomes which are involved in trafficking of miRNAs [57]. So
far, it is unclear if the systemic feedback signals conversely
influence cell intrinsic aging programs. We have previously
demonstrated that MSC reveal specific gene expression changes
[32] and DNA-methylation changes upon aging [36,58,59]. The
precise mechanisms that govern cell-intrinsic age-associated
epigenetic modifications are yet unclear, but theoretically they
might be influenced by systemic factors. Further research will
demonstrate if the effect of donor age of serum supplements is
directly exerted by growth factors or other stimulatory molecules –
or if it even feeds back on the cell-intrinsic aging program.
Conclusion
Up to now serum supplements are still required for culture
expansion of MSC. Our study supports the notion that age-
associated soluble factors affect stem and progenitor cells – and
this is also relevant for serum supplements in cell culture. Clinical
trials with HPL-expanded MSC have already been performed and
no adverse side effects were reported [60,61]. However, clinical
implications of our study should not be overstated. The clinical
potency of MSC is not necessarily reflected by proliferation or
in vitro differentiation potential – in the absence of reliable markers
for clinical potency the optimal culture conditions have to be
assessed for each application individually [13]. So far, the essential
factors in serum supplements are not yet fully defined. Our study
demonstrates that HPLs of younger donors enhance expansion
rates of MSC, but the variance of proliferation is relatively high
within HPL-age groups. Furthermore, MSC in clinical trials are
often used at earlier passages (2
nd to 3
rd passage), whereas some of
our results were generated with MSC at higher passages. HPL
derived from younger donors may be advantageous for enhanced
culture expansion, but the functional relevance can only be
assessed in clinical trials. The results of this study do not have a
clinical implication for the above mentioned reasons.
Supporting Information
Figure S1 Variability of human platelet lysates for MSC
expansion. MSC from bone marrow (A,C,E,G,I; n=4) and
adipose tissue (B,D,F,H,J; n=3) were cultured in parallel with
media supplemented with different HPLs. Proliferation was
assessed after 7 days using the MTT assay. Signal intensity was
normalized to the corresponding FCS control and analyzed in
relation to platelet counts of HPL donors (A,B), or to the
concentrations of PDGF-AB (C,D), TGF-b1 (E,F), bFGF (G,H)
and IGF-1 (I,J).
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Figure 5. Age-related concentration of growth factors and hormones in HPL media. Concentrations of PDGF-AB, bFGF, IGF-1, TGF-b1,
estradiol, parathormone, leptin and 1,25 vitamin D3 were measured in media supplemented with HPL from either younger donors (,35 years; n=5
to 7) or older donors (.45 years; n=5 to 8). None of these compounds revealed significant age-associated changes.
doi:10.1371/journal.pone.0037839.g005
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